Conditions

This post was originally published on this site TG Therapeutics’ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising response rates in patients with relapsed or refractory follicular lymphoma, according to new data from a Phase 2b clinical trial. The UNITY-NHL trial (NCT02793583) included 118 follicular lymphoma patients previously treated with at least…

This post was originally published on this site A simple blood test – which measures antibodies against certain tumor proteins, or antigens — may identify breast cancer up to five years before clinical signs of cancer are evident, but more research is needed to improve the test’s accuracy, a pilot study reports. Screening for a…

This post was originally published on this site Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are excited to launch the first-in-human clinical study of NKTR-255, which has shown promising and substantial anti-tumor activity in…

This post was originally published on this site Prostate-specific antigen (PSA) testing — a controversial approach to detecting prostate cancer — spotted the cancer more often, at a younger age, and in more serious forms in men older than 40 who carry mutations in the BRCA2 gene than in non-carriers, interim data of a large…

This post was originally published on this site Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared with chemotherapy alone, according to interim data of a Phase 3 study. AstraZeneca’s Imfinzi and the investigational tremelimumab…

This post was originally published on this site Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The supplemental New Drug Application (sNDA) requesting Imbruvica’s…

This post was originally published on this site The soluble interleukin 2 receptor (sIL-2R) is more sensitive and specific than the angiotensin-converting enzyme (ACE), one of the most common diagnostic biomarkers of sarcoidosis, at identifying people who might have the disease, a study found. The findings were reported in the study, “Sensitivity and specificity of…

This post was originally published on this site Commonly used in primary healthcare, blood tests for CA125 may help diagnose ovarian cancer and other types of cancer, particularly in older individuals, new research suggests. The findings were described in two presentations at the recent 2019 National Cancer Research Institute (NCRI) Conference in Glasgow, UK. The…

This post was originally published on this site For patients with gene mutations that increase their risk for diseases such as breast cancer, fertility and in vitro fertilization (IVF) center Shady Grove Fertility (SGF) is offering individualized testing to lower the risk of passing the mutation to their children. To educate patients about such interventions, as…

This post was originally published on this site CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating people with relapsed or refractory melanoma. The investigational probody CX-072 and Yervoy, developed by Bristol-Myers Squibb, are two…